# v5.4

## Related releases

## Data changes

### Gene

```
AIM2 Background Updated
AIM2 Summary Updated
AURKC Background Updated
AURKC Summary Updated
CAV1 Background Updated
CAV1 Summary Updated
COL5A1 Background Updated
COL5A1 Summary Updated
GSTO1 Background Updated
GSTO1 Summary Updated
HERPUD1 Background Updated
HERPUD1 Summary Updated
LZTS1 Background Updated
LZTS1 Summary Updated
NPM1 Background Updated
PICALM Background Updated
PICALM Summary Updated
PTK7 Background Updated
PTK7 Summary Updated
YWHAE Background Updated
YWHAE Summary Updated
```

### Alteration

```
AIM2 Deletion, Mutation Effect, Description Updated
AIM2 Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
AIM2 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AIM2 Deletion Added
AIM2 Truncating Mutations, Mutation Effect, Description Updated
AIM2 Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
AIM2 Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AIM2 Truncating Mutations Added
ALK DCTN1-ALK Fusion, Mutation Effect, Description Updated
ALK DCTN1-ALK Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ALK DCTN1-ALK Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ALK DCTN1-ALK Fusion Added
AR V7 Name Changed
	 New: V7
	 Old: AR-V7
AR V7, Mutation Effect, Description Updated
AR V567ES [v567es] Name Changed
	 New: V567ES [v567es]
	 Old: ARv567es
AR V567ES [v567es], Mutation Effect, Description Updated
AR V1, Mutation Effect, Description Updated
AR V1, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
AR V1, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
AR V1 Added
AR V2, Mutation Effect, Description Updated
AR V2, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
AR V2, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
AR V2 Added
AR V4, Mutation Effect, Description Updated
AR V4, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
AR V4, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AR V4 Added
AR V3, Mutation Effect, Description Updated
AR V3, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
AR V3, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AR V3 Added
AR V9, Mutation Effect, Description Updated
AR V9, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
AR V9, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
AR V9 Added
AR V5, Mutation Effect, Description Updated
AR V5, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
AR V5, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
AR V5 Added
AR V6, Mutation Effect, Description Updated
AR V6, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
AR V6, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
AR V6 Added
AURKC Amplification, Mutation Effect, Description Updated
AURKC Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
AURKC Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AURKC Amplification Added
BAP1 R150fs, Mutation Effect, Description Updated
BAP1 R150fs, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
BAP1 R150fs, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
BAP1 R150fs Added
BRCA2 D1781N, Mutation Effect, Description Updated
BRCA2 D1781N, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
BRCA2 D1781N, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
BRCA2 D1781N Added
CAV1 Amplification, Mutation Effect, Description Updated
CAV1 Amplification, Mutation Effect, Effect Updated
	 New: Gain-of-function
	 Old:
CAV1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CAV1 Amplification Added
CAV1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old: Gain-of-function
CAV1 Deletion, Mutation Effect, Description Updated
CAV1 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CAV1 Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CAV1 Deletion Added
CDH1 D254N, Mutation Effect, Description Updated
CDH1 D254N, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Loss-of-function
CDH1 D254N, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Yes
COL5A1 Amplification, Mutation Effect, Description Updated
COL5A1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
COL5A1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
COL5A1 Amplification Added
ERBB2 I767M, Mutation Effect, Description Updated
ESR1 S463F, Mutation Effect, Description Updated
ESR1 S463F, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ESR1 S463F, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant) Added
ESR1 S463F Added
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant) Name Changed
	 New: D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant)
	 Old: D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations)
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant) Added
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant) Added
ESR1 V422del Deleted
GSTO1 Amplification, Mutation Effect, Description Updated
GSTO1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
GSTO1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
GSTO1 Amplification Added
JAK2 R867Q, Mutation Effect, Description Updated
KRAS F156L, Mutation Effect, Description Updated
LZTS1 Deletion, Mutation Effect, Description Updated
LZTS1 Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
LZTS1 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
LZTS1 Deletion Added
LZTS1 Truncating Mutations, Mutation Effect, Description Updated
LZTS1 Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
LZTS1 Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
LZTS1 Truncating Mutations Added
MET L1195F, Mutation Effect, Description Updated
MET L1195F, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
MET L1195F, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
MET TRIM4-MET Fusion, Mutation Effect, Description Updated
MET TRIM4-MET Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET TRIM4-MET Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET TRIM4-MET Fusion Added
MET ZKSCAN1-MET Fusion, Mutation Effect, Description Updated
MET ZKSCAN1-MET Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET ZKSCAN1-MET Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET ZKSCAN1-MET Fusion Added
MLLT10 PICALM-MLLT10 Fusion, Mutation Effect, Description Updated
MYOD1 L122R, Mutation Effect, Description Updated
MYOD1 L122R, Mutation Effect, Effect Updated
	 New: Switch-of-function
	 Old: Likely Loss-of-function
NPM1 W288fs*12 Name Changed
	 New: W288fs*12
	 Old: W288fs
NPM1 W288fs*12, Mutation Effect, Description Updated
NPM1 W288fs*12, Mutation Effect, Oncogenic Updated
	 New: Yes
	 Old: Likely
NPM1 W290Rfs*10, Mutation Effect, Description Updated
NPM1 W290Rfs*10, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 W290Rfs*10, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 W290Rfs*10 Added
NPM1 NPM1-RPP30 Fusion, Mutation Effect, Description Updated
NPM1 NPM1-RPP30 Fusion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 NPM1-RPP30 Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 NPM1-RPP30 Fusion Added
NPM1 NPM1-CCDC28A Fusion, Mutation Effect, Description Updated
NPM1 NPM1-CCDC28A Fusion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 NPM1-CCDC28A Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 NPM1-CCDC28A Fusion Added
NPM1 L136_137insAEDVKLL, Mutation Effect, Description Updated
NPM1 L136_137insAEDVKLL, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 L136_137insAEDVKLL, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 L136_137insAEDVKLL Added
NPM1 S137_K137fs*, Mutation Effect, Description Updated
NPM1 S137_K137fs*, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 S137_K137fs*, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 S137_K137fs* Added
NPM1 K141_142insLSALSISGK, Mutation Effect, Description Updated
NPM1 K141_142insLSALSISGK, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 K141_142insLSALSISGK, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 K141_142insLSALSISGK Added
NPM1 K134_Q134insLLSGLQ, Mutation Effect, Description Updated
NPM1 K134_Q134insLLSGLQ, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 K134_Q134insLLSGLQ, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 K134_Q134insLLSGLQ Added
NPM1 L135insALELGN, Mutation Effect, Description Updated
NPM1 L135insALELGN, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 L135insALELGN, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 L135insALELGN Added
NPM1 NPM1-MLF1 Fusion, Mutation Effect, Description Updated
NPM1 NPM1-MLF1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 NPM1-MLF1 Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 NPM1-MLF1 Fusion Added
NPM1 Truncating Mutations, Mutation Effect, Description Updated
NPM1 Q252Lfs*7, Mutation Effect, Description Updated
NPM1 Q252Lfs*7, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 Q252Lfs*7, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 Q252Lfs*7 Added
NPM1 NPM1-HAUS1 Fusion, Mutation Effect, Description Updated
NPM1 NPM1-HAUS1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
NPM1 NPM1-HAUS1 Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 NPM1-HAUS1 Fusion Added
NPM1 W288fs*12, Mutation Effect, Effect Updated
	 New: Switch-of-function
	 Old: Likely Loss-of-function
NPM1 W290Rfs*10, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 NPM1-RPP30 Fusion, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 NPM1-CCDC28A Fusion, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 K134_Q134insLLSGLQ, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 L135insALELGN, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 NPM1-MLF1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 NPM1-HAUS1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations) Added
NPM1 118_153trunc [Truncating mutations in exon 5], Mutation Effect, Description Updated
NPM1 118_153trunc [Truncating mutations in exon 5], Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old:
NPM1 118_153trunc [Truncating mutations in exon 5], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 118_153trunc [Truncating mutations in exon 5] Added
NPM1 224_257trunc [Truncating mutations in exon 9], Mutation Effect, Description Updated
NPM1 224_257trunc [Truncating mutations in exon 9], Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old:
NPM1 224_257trunc [Truncating mutations in exon 9], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 224_257trunc [Truncating mutations in exon 9] Added
NPM1 283_294trunc [Truncating mutations in exon 11], Mutation Effect, Description Updated
NPM1 283_294trunc [Truncating mutations in exon 11], Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old:
NPM1 283_294trunc [Truncating mutations in exon 11], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
NPM1 283_294trunc [Truncating mutations in exon 11] Added
NPM1 Truncating Mutations Deleted
NPM1 L136_137insAEDVKLL, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 S137_K137fs*, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 K141_142insLSALSISGK, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 Q252Lfs*7, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old: Likely Loss-of-function
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134_Q134insLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations) Name Changed
	 New: 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134_Q134insLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations)
	 Old: 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations)
NPM1 S137Kfs*1 Name Changed
	 New: S137Kfs*1
	 Old: S137_K137fs*
NPM1 S137Kfs*1, Mutation Effect, Description Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134delinsQLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations) Name Changed
	 New: 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134delinsQLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations)
	 Old: 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134_Q134insLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations)
NPM1 K134delinsQLLSGLQ Name Changed
	 New: K134delinsQLLSGLQ
	 Old: K134_Q134insLLSGLQ
NPM1 K134delinsQLLSGLQ, Mutation Effect, Description Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCDC28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134delinsQLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations) Name Changed
	 New: 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCDC28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134delinsQLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations)
	 Old: 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion, K134delinsQLLSGLQ, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK (Susceptible NPM1 Mutations)
PICALM Amplification, Mutation Effect, Description Updated
PICALM Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PICALM Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PICALM Amplification Added
POLE L424P, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
POLE L424P, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PRKCI Amplification, Mutation Effect, Description Updated
PRKCI Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKCI Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PRKCI Amplification Added
RET R693H, Mutation Effect, Description Updated
RET R693H, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
RET R693H, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
RET R693H Added
TP53 N235S, Mutation Effect, Description Updated
TP53 N235S, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
TP53 N235S, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
TP53 N235S Added
YWHAE Amplification, Mutation Effect, Description Updated
YWHAE Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
YWHAE Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
YWHAE Amplification Added
YWHAE YWHAE-NUTM2A Fusion, Mutation Effect, Description Updated
YWHAE YWHAE-NUTM2A Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
YWHAE YWHAE-NUTM2A Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
YWHAE YWHAE-NUTM2A Fusion Added
YWHAE YWHAE-NUTM2B Fusion, Mutation Effect, Description Updated
YWHAE YWHAE-NUTM2B Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
YWHAE YWHAE-NUTM2B Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
YWHAE YWHAE-NUTM2B Fusion Added
```

### Evidence

```
AIM2 Gene Type, Tumor Suppressor Updated
ALK Fusions, Non-Small Cell Lung Cancer, Neladalkib, Description Updated
ALK G1202R, Non-Small Cell Lung Cancer, Neladalkib, Description Updated
AURKC Gene Type, Oncogene Updated
CAV1 Gene Type, Oncogene Updated
CAV1 Gene Type, Tumor Suppressor Updated
CDKN2A Oncogenic Mutations, All Solid Tumors, Palbociclib, Ribociclib, Abemaciclib, Description Updated
COL5A1 Gene Type, Oncogene Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant, Description Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Other Solid Tumor Types, Summary Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Summary Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant, FDA Level Updated
	 New: Fda2
	 Old: no
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant, Level Updated
	 New: 1
	 Old:
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant, Propagation to Other Liquid Tumor Types Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant, Propagation to Other Solid Tumor Types Updated
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant 1 Added
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Summary Updated
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant, FDA Level Updated
	 New: Fda2
	 Old: no
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant, Level Updated
	 New: 1
	 Old:
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant, Propagation to Other Liquid Tumor Types Updated
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant, Propagation to Other Solid Tumor Types Updated
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Other Tumor Types, Summary Updated
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Other Tumor Types Added
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Summary Updated
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant, Description Updated
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant, FDA Level Updated
	 New: Fda2
	 Old: no
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant, Level Updated
	 New: 1
	 Old:
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant, Propagation to Other Liquid Tumor Types Updated
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant, Propagation to Other Solid Tumor Types Updated
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer Added
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant 1 Added
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Other Tumor Types, Summary Updated
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Other Tumor Types Added
ESR1 S463F, Breast Cancer, Summary Updated
ESR1 S463F, Breast Cancer, Imlunestrant, Description Updated
ESR1 S463F, Breast Cancer, Imlunestrant, FDA Level Updated
	 New: Fda2
	 Old: no
ESR1 S463F, Breast Cancer, Imlunestrant, Level Updated
	 New: 1
	 Old:
ESR1 S463F, Breast Cancer, Imlunestrant, Propagation to Other Liquid Tumor Types Updated
ESR1 S463F, Breast Cancer, Imlunestrant, Propagation to Other Solid Tumor Types Updated
ESR1 S463F, Breast Cancer Added
ESR1 S463F, Breast Cancer, Imlunestrant 1 Added
ESR1 S463F, Other Tumor Types, Summary Updated
ESR1 S463F, Other Tumor Types Added
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant, Description Updated
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant 1 Added
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Elacestrant 1 Deleted
ESR1 D538, E380, Y537, L536, L469V, S463P (Oncogenic ligand-binding domain missense mutations for elacestrant and imlunestrant), Breast Cancer, Imlunestrant 1 Deleted
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer, Elacestrant, Description Updated
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer, Elacestrant, FDA Level Updated
	 New: Fda2
	 Old: no
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer, Elacestrant, Level Updated
	 New: 1
	 Old:
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer, Elacestrant, Propagation to Other Liquid Tumor Types Updated
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer, Elacestrant, Propagation to Other Solid Tumor Types Updated
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer Added
ESR1 D538, E380, Y537, L536, L469V, S463P, G422R, F461V (Level 1 Elacestrant), Breast Cancer, Elacestrant 1 Added
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer, Imlunestrant, Description Updated
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer, Imlunestrant, FDA Level Updated
	 New: Fda2
	 Old: no
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer, Imlunestrant, Level Updated
	 New: 1
	 Old:
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer, Imlunestrant, Propagation to Other Liquid Tumor Types Updated
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer, Imlunestrant, Propagation to Other Solid Tumor Types Updated
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer Added
ESR1 D538, E380, Y537, L536, L469V, S463P, S463F, V422del (Level 1 Imlunestrant), Breast Cancer, Imlunestrant 1 Added
ESR1 V422del (Oncogenic ligand-binding domain in-frame insertions or deletions), Breast Cancer, Imlunestrant 1 Deleted
ESR1 G442R, F461V (Oncogenic ligand-binding domain missense mutations for elacestrant), Breast Cancer, Elacestrant 1 Deleted
ESR1 S463F, Breast Cancer, Imlunestrant 1 Deleted
GSTO1 Gene Type, Oncogene Updated
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered, Summary Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Summary Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Dordaviprone, Description Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Dordaviprone, FDA Level Updated
	 New: Fda2
	 Old: no
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Dordaviprone, Level Updated
	 New: 1
	 Old:
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Dordaviprone, Propagation to Other Liquid Tumor Types Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Dordaviprone, Propagation to Other Solid Tumor Types Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma Added
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma, Dordaviprone 1 Added
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma Deleted
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma} Name Changed
	 New: Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}
	 Old:
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Summary Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Dordaviprone, Description Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Dordaviprone, FDA Level Updated
	 New: Fda2
	 Old: no
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Dordaviprone, Level Updated
	 New: 1
	 Old:
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Dordaviprone, Propagation to Other Liquid Tumor Types Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Dordaviprone, Propagation to Other Solid Tumor Types Updated
H3-3A K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Dordaviprone 1 Added
H3-3A K28M, Diffuse Midline Glioma, H3 K27-Altered Deleted
H3C2 K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma} Name Changed
	 New: Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}
	 Old: Diffuse Midline Glioma, H3 K27-Altered
H3C2 K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Summary Updated
H3C3 K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma} Name Changed
	 New: Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}
	 Old: Diffuse Midline Glioma, H3 K27-Altered
H3C3 K28M, Pediatric-Type Diffuse High-Grade Glioma {excluding Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Pediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype, Infant-Type Hemispheric Glioma}, Summary Updated
HERPUD1 Gene Type, Insufficient Evidence Updated
KMT2A Fusions, Acute Myeloid Leukemia, Revumenib, Description Updated
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib, Description Updated
KMT2A Fusions, B-Lymphoblastic Leukemia, Lymphoma, Revumenib, Description Updated
LZTS1 Gene Type, Tumor Suppressor Updated
NF1 Oncogenic Mutations, Neurofibroma, Summary Updated
NF1 Oncogenic Mutations, Neurofibroma, Selumetinib, Description Updated
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Summary Updated
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Revumenib, Description Updated
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Revumenib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Revumenib, Level Updated
	 New: 1
	 Old: 3A
NPM1 Gene Type, Oncogene Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Summary Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Revumenib, Description Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Revumenib, FDA Level Updated
	 New: Fda2
	 Old: no
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Revumenib, Level Updated
	 New: 1
	 Old:
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Revumenib, Propagation to Other Liquid Tumor Types Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Revumenib, Propagation to Other Solid Tumor Types Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Revumenib 1 Added
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Ziftomenib, Description Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Ziftomenib, FDA Level Updated
	 New: Fda2
	 Old: no
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Ziftomenib, Level Updated
	 New: 1
	 Old:
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Ziftomenib, Propagation to Other Liquid Tumor Types Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Ziftomenib, Propagation to Other Solid Tumor Types Updated
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia Added
NPM1 118_153trunc [Truncating mutations in exon 5], 224_257trunc [Truncating mutations in exon 9], 283_294trunc [Truncating mutations in exon 11], NPM1-CCD28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion (Susceptible NPM1 Mutations), Acute Myeloid Leukemia, Ziftomenib 1 Added
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Revumenib 1 Deleted
NTRK1 Fusions, All Solid Tumors, Entrectinib, Description Updated
NTRK2 Fusions, All Solid Tumors, Entrectinib, Description Updated
NTRK3 Fusions, All Solid Tumors, Entrectinib, Description Updated
PICALM Gene Type, Oncogene Updated
PTK7 Gene Type, Oncogene Updated
SMARCB1 R377C, Summary Updated
YWHAE Gene Type, Oncogene Updated
```
